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Background: In the recent years, a role of the immune system in Huntington’s disease (HD) is increasingly
recognized. Here we investigate the presence of T cell activating auto-antibodies against angiotensin II type 1
receptors (AT1R) in all stages of the disease as compared to healthy controls and patients suffering from multiple
sclerosis (MS) as a prototype neurologic autoimmune disease.
Results: As compared to controls, MS patients show higher titers of anti-AT1R antibodies, especially in individuals
with active disease. In HD, anti-AT1R antibodies are more frequent than in healthy controls or even MS and occur
in 37.9% of patients with relevant titers ≥ 20 U/ml. In a correlation analysis with clinical parameters, the presence
of AT1R antibodies in the sera of HD individuals inversely correlated with the age of onset and positively with the
disease burden score as well as with smoking and infection.
Conclusions: These data suggest a dysfunction of the adaptive immune system in HD which may be triggered by
different stimuli including autoimmune responses, infection and possibly also smoking.
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NeuroinflammationBackground
Huntington’s disease (HD) is a devastating, progressive
neurodegenerative disease with autosomal dominant in-
heritance, characterized by movement disorder, cognitive
decline and behavioral abnormalities. It is caused by a
trinucleotide CAG repeat expansion (≥36) in the gene
encoding the protein huntingtin, localized on chromo-
some 4 [1]. Over the last two decades, knowledge on the
pathophysiology and molecular biology of HD has sig-
nificantly extended and the contribution of non-CNS tis-
sues to pathogenesis and clinical symptomatology is
increasingly recognized. Besides changes in the CNS,
additional systemic abnormalities have been identified
including endocrine dysfunction and immune activation
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unless otherwise stated.observed in several neurodegenerative diseases which
may contribute to the cascade of events leading to neur-
onal degeneration [4-8]. In HD patients, activation of
the peripheral immune system and in particular an up
regulation of innate immune responses including micro-
glia activation has been repeatedly reported [9-11]. Yet,
only scarce data exist on the activation of adaptive im-
mune responses in HD which may be characterized by
an augmented T cell response or the presence of auto-
antibodies. One such approach was the detection of
anti-gliadin antibodies, which were detected in one study
in 44.2% of HD patients [12].
Candidate auto-antibodies involved in dysfunction of
the adaptive immune system are antibodies against
angiotensin II type 1 receptors (AT1R). AT1R mediates
the cellular effects of angiotensin II, the major effector
molecule of the renin angiotensin aldosterone system
(RAAS), which is a well-known regulator of salt homeo-
stasis and blood pressure. Yet, there is also some pivotal
evidence that angiotensin II and anti-AT1R antibodies. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline data of HD individuals and healthy
controls
Parameter HD individuals Healthy controls
(n = 132) (n = 129)
Age [yr] 46.9 ± 12.8 47.5 ± 9.8
(21–89) (22–56)
Weight [kg] 68.4 ± 14.3 73.4 ± 14
(40–101) (50–115, n = 103)
Height 171.7 ± 9.1 170 ± 9.7
(157–197) (150–191, n = 103)
Smoking [%] 34.8 34.4 (n = 125)
CAG expanded 44.7 ± 4.7 ———
(39–70)
Disease burden score 403.9 ± 133.6 ———
(91–825)
Onset motor [yr] 41.5 ± 12.1 ———
(10–72, n = 102)
Onset psychiatric [yr] 42.2 ± 12.1 ———
(15–73, n = 57)
Duration of disease [yr] 7.6 ± 5.1 ———
(0.1-23, n = 102)
YTO Langbehn [yr] 16.9 ± 9.1 ———
(5–43, n = 30)
UHDRS MS 41.9 ± 29.7 ———
(0–96)
UHDRS TFC 7.6 ± 4.5 ———
(0–13)
UHDRS IS 70.5 ± 26.5 ———
(10–100)
UHDRS CS 159.5 ± 108.8 ———
(0–379)
Tapping dominant 162 ± 43.7 ———
(65–233, n = 55)
Tapping non-dominant 139.1 ± 46.9 ———
(40–207, n = 55)
Peg board dominant [sec] 52.6 ± 13.6 ———
(32.5-88.5, n = 55)
Peg board non-dominant [sec] 58.6 ± 16.0 ———
(38.7-100, n = 55)
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particular, anti-AT1R antibodies may contribute to pre-
eclampsia and are involved in acute transplant rejection
and graft loss [13]. Further studies show that pre-
transplant sensitization against AT1R increased the risk
for acute rejection [14]. An antibody titer > 10 U/ml was
determined as independent risk factor for rejection. In
the autoimmune disease systemic sclerosis, anti-AT1R
antibodies may serve as biomarker for risk assessment of
disease progression, contribute to disease pathogenesis
and predict disease related mortality [15]. So far, an as-
sociation between anti-AT1R antibodies and neurode-
generative diseases has not been investigated. Here we
analyze the presence of anti-AT1R antibodies in HD
patients as compared to healthy controls and patients
suffering from multiple sclerosis (MS) as a prototypic
autoimmune disease associated with the production of
distinct auto-antibodies [16,17]. In HD, anti-AT1R anti-
bodies are present at high titers.
Results
Detection of anti-AT1R antibodies in HD individuals
In 132 HD participants with genetically definite HD
from all stages of the disease serum anti-AT1R anti-
bodies were analysed via ELISA. The main demographic
and clinical characteristics of HD subjects at the time
point of investigation are reported in Table 1. 46 partici-
pants were smokers, 18 had an infection, 16 reported
any kind of an allergy, 36 were on serotonin reuptake
inhibitors as an antidepressant medication, 59 on an
anti-dopaminergic drug and 78 took any kind of other
medication.
The mean anti-AT1 antibody titer in the HD cohort
was determined as 20.5 ± 12.8 U/ml which was signifi-
cantly higher than in healthy controls (mean titer: 8.6 ±
4.9 U/ml, Figure 1). Upon analysis of ranks close to
quartiles 23.8% of values were < 10 U/ml, 23.5% between
10–16 U/ml, 25.8% between 16–35 U/ml and 25% ≥ 35
U/ml. Assuming values > 15 U/ml as relevant titers, 71
of 132 patients (53.8%) display relevant anti-AT1R anti-
bodies. Assuming 20 U/ml as relevant cutoff, 50 of 132 HD
individuals (37.9%) displayed relevant anti-AT1R serum
antibodies. A total of 29 patients (21.9%) showed titers
reaching the ceiling value > 40 U/ml. There were no signifi-
cant titer differences between males and females.
In a selected cohort of nine patients, follow-up sam-
ples were collected one year later. Upon follow-up anti-
AT1R antibody titers were surprisingly stable and only
differed by a mean of 3.7 ± 4.3 U/ml (p = not significant).
Relevant titer changes (assuming the cutoff of 20 U/ml)
occurred only in 2/9 (22.2%) cases.
To further assess the significance of our finding in HD
individuals, we additionally analyzed the presence of
anti-AT1R antibodies in a cohort of a total of 97 MSpatients (baseline data given in Table 2). In the total co-
hort, 20/97 (20.6%) patients displayed titers > 15 U/ml,
13/97 (13.4%) displayed titers > 20 U/ml and 2/97 (2.1%)
showed titers reaching the ceiling value of > 40 U/ml.
The mean titer was 11.1 ± 8.6 U/ml which was signifi-
cantly lower than in HD individuals (Figure 1, p < 0.001).
In the total MS cohort, antibody titers did not correlate
with disease duration, disease course (RR-MS vs. SP-
Figure 1 Dot plot graph showing anti-AT1R antibody titers
(U/ml) in HD individuals (n = 132), MS patients (n = 97) and
healthy controls (n = 129).
Table 3 Correlation of anti-AT1R antibodies with clinical
features of HD individuals
R-value P-value
Age - 0.03 0.732
Gender 0.119 0.175
Height 0.044 0.646
Body weight 0.009 0.925
Onset motor - 0.23 0.02*
Onset psychiatric −0.23 0.095
Duration of disease 0.18 0.035*
UHDRS 0.22 0.012*
TFC - 0.18 0.03*
IS −0.21 0.016*
CAG not-expanded 0.02 0.822
CAG expanded 0.155 0.076
CAG Index 0.18 0.04*
Year to onset (YTO) Langbehn 0.092 0.627
Shoulson scale 0.15 0.087
Neuroleptic Intake 0.149 0.088
SSRI intake −0.63 0.473
Other Medication 0.011 0.897
Smoking −0.26 0.005**
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modulatory treatment. However, MS patients with active
disease defined as relapse or MRI activity in the previous
3 months displayed higher antibody titers than patients
with stable relapsing-remitting or progressive disease
(mean 25.6 ± 11.8 versus 12.0 ± 7.1 U/ml, n = 9 versus
89; p = 0.0005).
Correlation of anti-AT1R antibodies with clinical
symptoms in HD
In a next step, we correlated absolute antibody values
with clinical features of our HD cohort. Parameters in-
cluded baseline information (age, gender, height, body
weight), medication (neuroleptics, SSRI, other), informa-
tion of disease onset (onset of motor symptoms, onset of
psychiatric symptoms), scales for clinical disease stage
(UHDRS, independency scale (IS), total functional capacityTable 2 Baseline data of MS patients, n = 97
Parameter MS individuals
Mean Age (years ± SD) 39.3 ± 10.2
Gender Male/Female (%) 40.2/59.8%
Disease Course RR-MS/SP-MS (%) 80.4/19.6%
Disease Duration (years ± SD) 7.0 ± 5.4
Median EDSS (range) 2.5 (0–8.5)scale (TFC), disease duration and CAG repeats, measures
of neuropsychology (CS) and motor function (MS) includ-
ing more quantitative motor measures like tapping or
peg board results and finally infection, smoking and allergy
(Table 3). Antibody titers significantly correlated with
motor onset of disease (r = −0.23; p = 0.02), duration of dis-
ease (r = 0.18, p = 0.035), UHDRS-MS (r = 0.22, p = 0.012),
TFC (r = −0.18, p = 0.03) and IS (r = −0.21, p = 0.016) as
well as disease burden score (r = 0.18, p = 0.04). The higher
the antibody titer, the earlier was the onset of disease. Yet,
antibody titers also significantly correlated with smoking
(r = −0.26, p = 0.005) and the presence of infection at sam-
pling (r = 0.27, p = 0.002), but not with allergies. Similar
results were obtained when correlating these clinical fea-
tures with quartiles of anti-AT1R antibodies or when as-
suming 15 U/ml as cutoff for positive titers (data not
shown). In contrast, antibody titers did not correlate with
smoking in the healthy control group (r = 0.022, p = 0.76).Infection 0.27 0.002**
Allergy 0.097 0.268
Tapping dominant −0.01 0.921
Tapping non-dominant 0.0 0.998
Peg board dominant 0.001 0.992
Peg board non-dominant 0.088 0.992
Significant correlations are shown in bold, asterisks denote significance with
*p < 0.05, **p < 0.001.
Table 4 Modelling the relation of anti-AT1R antibodies in
HD individuals to disease-related outcomes and smoking
as well as infection
Standardized Beta T p-Value
Model - Step 1 IS - 0.50 - 4.0 < 0.0001
Model - Step 2 IS 0.50 - 4.3 < 0.0001
CAG expanded 0.30 2.5 0.016
Model - Step 3 IS 1.1 - 3.9 < 0.0001
CAG expanded 0.30 2.6 0.014
Shoulson 0.60 - 2.2 0.03
A linear regression was performed to predict anti-AT1R antibody titers via
infection, smoking and HD-relevant variables with additional variables “onset
motor” and “onset psychiatric” (n = 48, i.e. only smokers with infection and
motor as well as psychiatric onset of disease were included). A stepwise
analysis revealed in a first step independence scale (IS), in a second step CAG
expanded and in a third step the variable Shoulson scale as predictor. Other
variables were not relevant for predicting the presence of anti-AT1R antibody
titers in this subgroup.
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of the disease (Shoulson stage 4 and 5; n = 107 remaining),
there were no significant correlations of absolute antibody
titers with clinical data. Yet in this very subgroup of
patients, the presence of anti-AT1R antibodies (cutoff 20
U/ml) did correlate with motor onset of disease (r = −0.28;
p = 0.016) and psychiatric onset of disease (r = −0.36;
p = 0.026).
In contrast, anti-AT1R antibodies did not correlate
with age, gender, body height or body weight, medica-
tion, motor or neuropsychological function, CAG repeat
length, Shoulson scale, years to onset or disease duration
in HD individuals.
After numerical calculation of antibody titers >40 to
obtain exact values (n = 132, mean 32.7 ± 37.4; range: 2.9
to 146.5), titers did not correlate with motor age of onset
any more, but we now found stronger correlations with
duration of disease (r = 0.244, p = 0.005), UHDRS-MS
(r = 0.367, p < 0.001), TFC (r = −0.344, p < 0.001) and IS
(r = −0.415, p < 0.001) as well as disease burden score (r =
0.302, p = 0.001). In addition, there was a significant cor-
relation with cognitive sum score (r = −0.293, p = 0.001),
and expanded CAG (r = 0.193, p = 0.027). Antibody titers
still significantly correlated with smoking (r = −0.264, p =
0.004) and the presence of infection at sampling (r = 0.315,
p < 0.001), but not with allergies.
Modeling the relevance of anti-AT1R antibodies in HD
In regression analyses, we modeled the prediction of
antibody titers by smoking and infection versus HD re-
lated variables in step wise models. Smoking as well as
infection were significant predictors for the presence of
anti-AT1R antibodies and explained 15% of the variance
(r2 = 0.151). When including the HD relevant variables
independence scale (IS), CAG expanded and Shoulson
scale as well as “motor” or “psychiatric onset” of disease
to the model, IS alone explains 25.8%, IS and CAG ex-
panded together explain 34.8% and all variables explain
41.5% of the variance (r2 = 0.415). A final stepwise
model included independence scale (IS) as predictor and
as next steps the variables “onset motor” and smoking.
IS alone explains 14.5% of the variance, IS and onset
motor together explain 19.2% of the variance, IS and
“onset motor” and smoking together explain 23.7% of
the variance (Table 4).
A covariate analysis of HD patients suffering from psy-
chiatric symptoms (“psychiatric onset”) showed that only
the presence of anti-AT1R antibodies (cutoff 20 U/ml),
but not smoking or infection was a significant covariate.
Further covariate analyses of the variables disease bur-
den score, duration of disease or Shoulson scale after
grouping according to the presence of antibody titers
and smoking as well as infection as co-variates revealed
infection as significant covariate in all analyses.Upon exclusion of smokers and participants with in-
fection from the HD cohort, a total of 55 individuals
remained left for further analyses. The mean anti-AT1R
antibody titer in this group was 21.1 ± 12.1 U/ml which
was still significantly higher than in the MS cohort and
in healthy controls (each p < 0.0001). Assuming an anti-
body titer of 20 U/ml as cutoff, statistical analyses by
Mann–Whitney testing confirmed significant differences
between patients with or without significant anti-AT1R
antibody titers for “onset motor” (p = 0.046) and “onset
psychiatric” (p = 0.044). For the variables “onset” and
“years to onset”, there was a trend in this cohort to-
wards earlier time points in the antibody positive sub-
group (n = 55, p = 0.096).
Discussion
In this study, we found that anti-AT1R antibodies are
present in HD individuals and MS patients at high titers.
The positive detection of anti-AT1R antibodies in the
sera of MS patients was associated with recent disease
activity. In HD individuals, anti-AT1R antibody titers in-
versely correlated with the age of onset and were also
linked to smoking and infection.
The presence of anti-AT1R IgG antibodies in HD im-
plies an increased activity of the adaptive immune sys-
tem and in particular B cell and plasma cell activity in
HD patients. Yet, there are no data on a general in-
creased IgG production or a general increase of auto-
antibodies in HD patients. So far, the only auto-antibody
described in HD is the detection of anti-gliadin anti-
bodies in 44.2% of HD patients [12]. Here, further stud-
ies on subsets of the B cells lineage and antibody profiles
in HD are clearly of interest.
MS patients display higher anti-AT1R IgG antibodies
than healthy controls. The finding of anti-AT1R anti-
bodies in MS adds this antibody to a range of different
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proteins, most recently e.g. the Kir4.1 potassium channel
[16-19]. Although these antibody may play a patho-
physiological role, MS is generally viewed as a primarily
T cell mediated autoimmune disease. The concept of
anti-AT1R antibodies as drivers of increased T cell re-
sponses was already proven in renal transplant rejection
and rheumatologic disease [13,20]. Thus the finding of
anti-AT1R antibodies with particularly high titers in
patients with active disease is well in line with the patho-
physiological role of these auto-antibodies in other dis-
eases and also with the presumed pathomechanisms of
MS [21]. The role of anti-AT1R antibodies as a new
marker of disease activity in relapsing-remitting MS de-
serves further investigation in longitudinal studies.
The presence of anti-AT1R antibodies in HD also ar-
gues for an increased activation of T cells in HD patients
which harbor AT1R. In autoimmune disease (see above),
the role of T cells is much better established than in HD
which has essentially been characterized as a genetically
mediated neurodegenerative disease. Yet, a role for the
innate immune system in HD is increasingly recognized
and immune factors may constitute modifiers of the
disease. So far, data on the adaptive immune response
in HD only refer to some studies on cytokines like
interleukin-4 or lymphocyte numbers. However, the sig-
nificance of T cells to the pathophysiology of the disease
is still largely unclear. Our findings in HD further add to
the notion of an interlocking of inflammatory and pos-
sibly also neuroinflammatory processes on the one hand
and neurodegenerative processes on the other hand. Our
observations well match with recent reports contributing
to an increasingly recognized role of the immune system
in HD [22,23]. Indeed, an over-active adaptive immune
response in the peripheral blood as indicated by or even
driven by the presence of anti-AT1R antibodies may has-
ten the onset of disease and thus contribute to neurode-
generation. Further studies on the role of on the role of
the adaptive immune system and in particular effects of
anti-AT1R antibodies on T cell function in HD and also
other neurodegenerative diseases are warranted. Indeed,
immune factors like anti-AT1R antibodies may add to the
determinants influencing age of onset and rate of progres-
sion in HD which were previously discussed [24,25].
It is tempting to speculate that auto-antibody produc-
tion and dysfunction of the adaptive immune system in
HD may be directly triggered by huntingtin aggregates
and mitochondrial dysfunction in immune cells. This
process may mimic a premature ageing of the immune
system as the disease progresses. Mitochondrial dysfunc-
tion is a well-known part in the pathophysiology of HD
and may lead to oxidative stress [26-30]. In immune cells,
oxidative stress is discussed to induce inflammasomes and
mitochondrial dynamics are known to influence T cellfunction [31]. A direct link between inflammatory pro-
cesses and mitochondrial dysfunction in T cells is also
supported by severe ultra-structural mitochondrial
changes in lymphoblasts from homozygous HD patients
[32]. Interestingly, there is a correlation between anti-
AT1R antibody titer and onset of HD, but no correlation
between anti-AT1R titer and years to onset. These data
may argue for a role of anti-AT1R not in the pre-
symptomatic phase, but rather during the course of the
manifest disease. This observation may additionally speak
for the HD related specificity of our findings and against a
pure association with (over the course of the disease un-
changed) life style factors (see below).
In our study, the presence of anti-AT1R antibodies
also correlates with smoking and infection in HD indi-
viduals. Statistical modelling argues for some smoking
and infection independent effects of HD and anti-AT1R
antibody titers still remain significantly higher after
exclusion of smokers and individuals with infections
were excluded. The specificity of these data is further
strengthened by the lack of a similar association in healthy
individuals. Possibly, smoking may serve as a trigger in a
susceptible population for the generation of anti-AT1R
auto-antibodies at a certain disease stage. Thus, it is easily
conceivable that infection or subclinical airway inflamma-
tion induced by smoking may directly or indirectly con-
tribute to the induction of auto-antibodies. In addition, it
cannot be excluded that also ageing may contribute to the
generation of anti-AT1R antibodies in humans. Yet, our
control cohort is well-matched to HD individuals thus ra-
ther excluding a confounding factor. In addition, previous
studies on anti-AT1R antibodies did not describe an in-
creased frequency of this auto-antibody with age alone
and the presence of significant anti-AT1R antibody titers
in HD individuals did not correlate with age in our cohort.
In view of the presence of anti-AT1R antibodies in dif-
ferent autoimmune and cardiovascular diseases and HD,
this antibody is obviously not disease-specific, but rather
indicates a general, but disease-related mechanism for
dysfunction of the adaptive immune system which may
be triggered by different stimuli including autoimmune
responses, infection and possibly also smoking.
In synopsis of the relation of anti-AT1R antibodies
with smoking and onset of HD symptoms, it is tempt-
ing to speculate that life style factors such as smoking
may directly influence the course of the disease via ef-
fects on the immune system. Indeed, the lung as organ
affected by smoking has recently been implicated as
an important regulator in T cell function [33]. In HD,
anti-AT1R antibodies may provide a direct molecular
link connecting smoking, an increased activation of
the immune system and neurodegeneration. Similar asso-
ciations between life style modifiers and progression of
neurologic disease have recently been investigated for
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HD [34,35].
In summary, we show the presence of anti-AT1R anti-
bodies in HD with a higher frequency than in MS pa-
tients and in healthy controls. Anti-AT1R antibodies
correlated with disease activity in MS and with onset of
disease and disease burden scores in HD. Future studies
in HD and MS also including transfer experiments in
animal models are needed to determine the exact patho-
genic role of this antibody response.
Material and methods
HD subjects
HD subjects were recruited at the Department of
Neurology, Ruhr University of Bochum. 132 genetically
confirmed HD mutation carriers (72 (54.5%) women and
60 (45.4%) men; mean age 46.9 ± 12.8 years) were screened
for anti-AT1R antibodies. 30 of the 132 HD mutation
carriers were classified as pre-manifest (preHD), based on
expert raters’ assessments of motor signs which were not
sufficient for the diagnosis of HD (Diagnostic Confidence
Level [DCL], item 17 of the UHDRS Motor Assessment)
[36]. Sixteen participants of the 102 manifest HD partici-
pants were in Shoulson stage I, 35 in stage II, 26 in stage
III, seventeen in stage IV and eight in Shoulson stage V, re-
spectively (see also Table 1) [37]. In a subgroup of nine pa-
tients, follow-up was after 12 months. At each assessment,
the following data and scores were determined: age, gen-
der, weight, height and smoking behavior as well as scores
on the motor (MSc), cognitive (verbal fluency test, symbol
digit modalities test, Stroop color, Stroop word and Stroop
interference, summarized as cognitive score (CS)), and in-
dependence (IS), as well as functional sections (TFC) of
the validated Unified Huntington’s Disease rating scale
(UHDRS) [36]. If possible, fine motor skills were measured
by simple (tapping; higher motor impairment leads to
lower test results) or complex (pegboard; higher motor
impairment leads to higher test results) quantitative
movement tests [38,39]. Years to disease onset (YTO)
for the preHD subjects were calculated by subtracting
the subject’s age at the time of investigation from his
or her estimated onset age using Langbehn’s formula
[40]. Moreover we calculated the disease burden score
(DBS = [CAG repeat - 35.5] × age) for each subject
[41]. Additionally, patients were interviewed about
medical problems including allergy, severe other
diseases, medication intake and the presence of infec-
tions. Infections were excluded clinically for outpa-
tients and excluded or confirmed clinically and by
determination of the C-reactive protein for inpatients
(all cases with Shoulson stage III to V) and all cases
clinically suspicious for an infection. Patients with
severe other diseases, such as a carcinoma, were
excluded.MS patients and healthy controls
A cohort of MS patients from Bochum or NeuroCure
Center, Berlin, Charité was enrolled in this study. Diag-
nosis was confirmed by the treating neurologist based
on the revised 2010 McDonald clinical and radiologic
criteria for MS [42]. 59.8% of MS patients were female
and 40.2% male, mean age was 39.3 ± 10.2 years, 80.4%
had relapsing remitting (RR-MS) and 19.6% had second-
ary progressive MS (SP-MS, see Table 2). 69.1% of
patients received a disease modifying therapy with in-
jectables (beta interferon or glatiramer acetate), 15.5%
were without treatment, 12.3% received a second line
therapy (natalizumab, mitoxantrone) and 3.1% were on
other treatments. Data from MS patients were correlated
with clinical course, disease modifying treatment, relapse
and MRI activity and disability (expanded disability
score scale, EDSS). Active disease was defined as re-
lapse or MRI activity in the last 3 months prior to
serum sampling.
Healthy controls were recruited at the University
Hospitals of Goettingen and Erlangen after obtaining in-
formed consent. 70.5% of control individuals were fe-
male and 29.5% male. Controls were matched to HD
subjects for age (47.5 ± 9.8 years) and smoking status
(34.4% smokers in the control group vs 34.8% in the HD
group, see also Table 1.
Solid-phase enzyme linked immunosorbent assay
Written informed consent to use serum samples for re-
search purposes was obtained from each individual.
Samples were collected in a standardized manner and
were analyzed for antibodies against the AT1R. A com-
mercially available sandwich enzyme linked immuno-
sorbent assay (ELISA; CellTrend GmbH, Luckenwalde,
Germany) to measure anti-AT1R autoantibodies was
employed as described previously [13-15]. Briefly, micro-
titer 96-well polystyrene plates were coated with extracts
from Chinese hamster ovary cells overexpressing the hu-
man AT1R. To maintain the conformational epitopes of
both receptors, 1 mM calcium chloride was added to
each buffer. Duplicate samples of a 1:100 serum dilution
were incubated at 4°C for 2 h. After washing steps,
plates were incubated for 60 min with a 1:20000 dilution
of horseradish peroxidase-labelled goat anti-human IgG
(Jackson, West Grove, Pennsylvania, USA) used for de-
tection. In order to obtain a standard curve, plates were
incubated with a ready-to use standard at 2.5, 5, 10, 20,
and 40 U/ml. The assay was validated as compared to a
cardiomyocyte bioassay (for further assay details see also
Dragun) [43]. The ELISA was validated according to the
Food and Drug Administration’s ‘Guidance for Industry:
Bioanalytical Method Validation’. The inter-assay variability
was 7% and the intra-assay variability was 6%. Persons who
were unaware of the patients’ characteristics performed the
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as “40”, values equal to or below the detection limit of 2.5
U/l were counted as “2.5”. In post-hoc analyses, numerical
calculations were performed to obtain exact values for titers
reaching the ceiling value > 40 U/ml.
Ethics
The study was approved by the local ethics committees in
Erlangen, Goettingen, Bochum and Berlin (Nr 3184–08
Ruhr-University Bochum and ZS EK 13 255/07 Berlin)
and was conducted in accordance to the Declaration of
Helsinki in its currently applicable form, the guidelines of
the International Conference on Harmonization of Good
Clinical Practice (ICH-GCP) and the applicable German
laws. Participants or their legal guardians gave written in-
formed consent.
Statistical analysis
Statistical analysis of baseline data and comparison between
groups was performed using chi-square-, Mann–Whitney
U- and Kruskal Wallis tests calculated via PRISMS (Graph-
Pad Software, Inc., La Jolla, CA, USA). Testing of probabil-
ity distributions in our samples was performed using
Kolmogorow-Smirnov-test. The association between anti-
AT1R antibodies of each participant and type of onset,
smoking (defined as regular nicotine consumption ever
day; yes/no), infection (yes/no), UHDRS-MS, IS, TFS, CS
and DBS was tested by correlation and linear regression
models controlling for anti-AT1R antibody titers. For cor-
relation analysis, Spearman-Rho analysis was used for non-
parametric data and Pearson analysis if data showed normal
distribution. Testing for significance was achieved by using
Wald- chi-square-test. Correlation analysis and linear
regression were computed using PASW-Statistics 18
(IBM SPSS, NY, USA). Significance was accorded to
p-values *p < .05; **p < .01; ***p < .001.
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